Skip to main content
PAHC
NASDAQ Life Sciences

Phibro Animal Health Appoints Daniel Bendheim as CEO, Grants Performance-Based RSUs with Aggressive Stock Price Targets

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$31.69
Mkt Cap
$1.285B
52W Low
$24.585
52W High
$60.08
52W Position info
29% above low
Off High info
47% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

PAHC sits 29% above its 52-week low of $24.585.

Summary

Phibro Animal Health has appointed Daniel Bendheim as its new CEO, effective July 1, 2026, and granted him 300,000 performance-based restricted stock units tied to ambitious stock price targets of $70-$100 by 2031.


Key Events · Executive and Board Changes · PAHC

  • New CEO Appointed

    Daniel Bendheim has been appointed Chief Executive Officer and President, effective July 1, 2026.

  • Significant Performance-Based RSU Grant

    Mr. Bendheim received a grant of 300,000 restricted stock units (RSUs), valued at approximately $9.5 million at the current stock price.

  • Aggressive Stock Price Vesting Targets

    The RSUs are performance-based and will vest on June 30, 2031, only if the company's 90-day average stock price reaches between $70 and $100, indicating a strong incentive for significant share price appreciation.

  • New Compensation Package

    The new CEO's employment agreement includes an annual base salary of $850,000, with target annual bonus and RSU awards each at 50% of his base salary.


Analysis · PAHC · Life Sciences

This filing announces a significant leadership change with the appointment of Daniel Bendheim as the new CEO and President. The accompanying performance-based RSU grant of 300,000 shares is substantial, valued at approximately $9.5 million at current prices. Crucially, these RSUs only vest if the company's stock price reaches between $70 and $100 by June 2031, representing a 121% to 216% increase from the current price. This highly incentivizes the new CEO to drive significant long-term shareholder value.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.3% of the 1982 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PAHC was trading at $31.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $24.59 to $60.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PAHC - Latest Insights

PAHC
Nov 04, 2026, 4:22 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $39.32
Real-time Price: $35.97 info
Change: -$3.35 (-9%) info
Market Cap: $1.46B info
PAHC
Aug 26, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $35.93
Real-time Price: $35.97 info
Change: +$0.040 (+0.11%) info
Market Cap: $1.46B info
PAHC
Aug 26, 2026, 4:20 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $35.93
Real-time Price: $35.97 info
Change: +$0.040 (+0.11%) info
Market Cap: $1.46B info
PAHC
Aug 26, 2026, 4:14 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $35.93
Real-time Price: $35.97 info
Change: +$0.040 (+0.11%) info
Market Cap: $1.46B info
PAHC
May 22, 2026, 4:24 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $33.26
Real-time Price: $35.97 info
Change: +$2.71 (+8%) info
Market Cap: $1.46B info